7% Off
Trileptal300 mg
Novartis (Bangladesh) Ltd.
৳186.56
Add to cart
Oxetol300 mg
Tablet
By
Best PriceTk /
1
Alternatives
Price
Medicine overview
Indications of Oxetol 300 mg
Oxetol 300 mg is indicated for:Adults: Monotherapy or adjunctive therapy in the treatment of partial seizuresPediatrics:
Monotherapy in the treatment of partial seizures in children 4-16 years
Adjunctive therapy in the treatment of partial seizures in children 2–16 years
Theropeutic Class
Adjunct anti-epileptic drugs
Pharmacology
The pharmacological activity of Oxetol 300 mg is primarily exerted through the metabolite derivative (the monohydroxy derivative, MHD) of Oxetol 300 mg.
Absorption
The mechanism of action of Oxetol 300 mg and MHD is thought to be mainly based on blockade of voltage-sensitive sodium channels, thus resulting in stabilization of hyper excited neural membranes, inhibition of repetitive neuronal firing and diminishment of propagation of synaptic impulses.
Dosage & Administration of Oxetol 300 mg
Adults
Dosage:initiate with a dose of 600 mg/day, given twice-a-day Adjunctive Therapy: Maximum increment of 600 mg/day at approximately weekly intervals
Notes:The recommended daily dose is 1200 mg/day Conversion to Monotherapy: withdrawal concomitant over 3 to 6 weeks;reach maximum dose of Oxetol 300 mg in 2 to 4 weeks with increments of 600 mg/day at weekly intervals to a recommended daily dose of 2400 mg/day Initiation of Monotherapy: Increments of 300 mg/day every third day to a dose of 1200 mg/day
Creatinine Clearance <30 mL/min
Dosage:Initiate at one half the usual starting dose and increase slowly Pediatrics: initiation with 8 to 10 mg/kg/day, given twice-a-day
Notes:For patients aged 2 to <4 years and under 20 kg, a starting dose of 16 to 20 mg/kg/day may be considered. Recommended daily dose is dependent upon patient weight
Adjunctive Patients (Aged 2–16 Years)
Dosage:For patients aged 4 to 16 years, target maintenance dose should be achieved over 2 weeks
Notes:For patients aged 2 to <4 years, maximum maintenance dose should be achieved over 2 to 4 weeks and should not to exceed 60 mg/kg/day Conversion to Monotherapy for Patients (Aged 4-16 Years): Maximum increment of 10 mg/kg/day at weekly intervals, concomitant antiepileptic drugs can be completely withdrawn over 3 to 6 weeks Initiation of Monotherapy for Patients (Aged 4–16 Years): Increments of 5 mg/kg/day every third day
| Condition | Dosage | Notes |
|---|---|---|
| Adults | initiate with a dose of 600 mg/day, given twice-a-day Adjunctive Therapy: Maximum increment of 600 mg/day at approximately weekly intervals | The recommended daily dose is 1200 mg/day Conversion to Monotherapy: withdrawal concomitant over 3 to 6 weeks;reach maximum dose of Oxetol 300 mg in 2 to 4 weeks with increments of 600 mg/day at weekly intervals to a recommended daily dose of 2400 mg/day Initiation of Monotherapy: Increments of 300 mg/day every third day to a dose of 1200 mg/day |
| Creatinine Clearance <30 mL/min | Initiate at one half the usual starting dose and increase slowly Pediatrics: initiation with 8 to 10 mg/kg/day, given twice-a-day | For patients aged 2 to <4 years and under 20 kg, a starting dose of 16 to 20 mg/kg/day may be considered. Recommended daily dose is dependent upon patient weight |
| Adjunctive Patients (Aged 2–16 Years) | For patients aged 4 to 16 years, target maintenance dose should be achieved over 2 weeks | For patients aged 2 to <4 years, maximum maintenance dose should be achieved over 2 to 4 weeks and should not to exceed 60 mg/kg/day Conversion to Monotherapy for Patients (Aged 4-16 Years): Maximum increment of 10 mg/kg/day at weekly intervals, concomitant antiepileptic drugs can be completely withdrawn over 3 to 6 weeks Initiation of Monotherapy for Patients (Aged 4–16 Years): Increments of 5 mg/kg/day every third day |
Dosage of Oxetol 300 mg
Adults
Dosage:initiate with a dose of 600 mg/day, given twice-a-day Adjunctive Therapy: Maximum increment of 600 mg/day at approximately weekly intervals
Notes:The recommended daily dose is 1200 mg/day Conversion to Monotherapy: withdrawal concomitant over 3 to 6 weeks;reach maximum dose of Oxetol 300 mg in 2 to 4 weeks with increments of 600 mg/day at weekly intervals to a recommended daily dose of 2400 mg/day Initiation of Monotherapy: Increments of 300 mg/day every third day to a dose of 1200 mg/day
Creatinine Clearance <30 mL/min
Dosage:Initiate at one half the usual starting dose and increase slowly Pediatrics: initiation with 8 to 10 mg/kg/day, given twice-a-day
Notes:For patients aged 2 to <4 years and under 20 kg, a starting dose of 16 to 20 mg/kg/day may be considered. Recommended daily dose is dependent upon patient weight
Adjunctive Patients (Aged 2–16 Years)
Dosage:For patients aged 4 to 16 years, target maintenance dose should be achieved over 2 weeks
Notes:For patients aged 2 to <4 years, maximum maintenance dose should be achieved over 2 to 4 weeks and should not to exceed 60 mg/kg/day Conversion to Monotherapy for Patients (Aged 4-16 Years): Maximum increment of 10 mg/kg/day at weekly intervals, concomitant antiepileptic drugs can be completely withdrawn over 3 to 6 weeks Initiation of Monotherapy for Patients (Aged 4–16 Years): Increments of 5 mg/kg/day every third day
| Condition | Dosage | Notes |
|---|---|---|
| Adults | initiate with a dose of 600 mg/day, given twice-a-day Adjunctive Therapy: Maximum increment of 600 mg/day at approximately weekly intervals | The recommended daily dose is 1200 mg/day Conversion to Monotherapy: withdrawal concomitant over 3 to 6 weeks;reach maximum dose of Oxetol 300 mg in 2 to 4 weeks with increments of 600 mg/day at weekly intervals to a recommended daily dose of 2400 mg/day Initiation of Monotherapy: Increments of 300 mg/day every third day to a dose of 1200 mg/day |
| Creatinine Clearance <30 mL/min | Initiate at one half the usual starting dose and increase slowly Pediatrics: initiation with 8 to 10 mg/kg/day, given twice-a-day | For patients aged 2 to <4 years and under 20 kg, a starting dose of 16 to 20 mg/kg/day may be considered. Recommended daily dose is dependent upon patient weight |
| Adjunctive Patients (Aged 2–16 Years) | For patients aged 4 to 16 years, target maintenance dose should be achieved over 2 weeks | For patients aged 2 to <4 years, maximum maintenance dose should be achieved over 2 to 4 weeks and should not to exceed 60 mg/kg/day Conversion to Monotherapy for Patients (Aged 4-16 Years): Maximum increment of 10 mg/kg/day at weekly intervals, concomitant antiepileptic drugs can be completely withdrawn over 3 to 6 weeks Initiation of Monotherapy for Patients (Aged 4–16 Years): Increments of 5 mg/kg/day every third day |
Interaction of Oxetol 300 mg
Oxetol 300 mg and its metabolite inhibit the enzyme CYP2C19 and therefore, interactions could arise when co-administering high doses of Oxazep with medicinal products that are metabolised by CYP2C19 (e.g. phenobarbital, phenytoin). Concurrent use of Oxazep with hormonal contraceptives may render few contraceptives ineffective (e.g. Ethinylestradiol and Levonorgestrel preparations). Co-administration of Oxazep lowers AUC of felodipine and Verapamil decreases bioavailability of MHD.
Contraindications
It is contraindicated to patients with hypersensitivity to the active substance or to any of the excipients.
Side Effects of Oxetol 300 mg
The most commonly reported adverse reactions are somnolence, headache, dizziness, diplopia, nausea; vomiting and fatigue. Very rarely clinically significant hyponatraemia can develop during Oxazep use. Class I (immediate) hypersensitivity reactions including rash, pruritus, urticaria, angioedema and reports of anaphylaxis have been received.
Pregnancy & Lactation
Pregnancy: Data on a limited number of pregnancies indicate that Oxetol 300 mg may cause serious birth defects (e.g. cleft palate) when administered during pregnancy. In the newborn child. Bleeding disorders in the newborn caused by antiepileptic agents have been reported. As a precaution, vitamin K1 should be administered as a preventive measure in the last few weeks of pregnancy and to the newborn. Oxetol 300 mg and its active metabolite (MHD) cross the placenta. Neonatal and maternal plasma MHD concentrations were similar in one case.Lactation: Oxetol 300 mg and its active metabolite (MHD) are excreted in human breast milk. Therefore, Oxazep should not be used during breast-feeding.
Precautions & Warnings
Alcohol: Caution should be exercised if alcohol is taken in combination with Oxazep therapy, due to a possible additive sedative effect.Withdrawal: As with all antiepileptic medicinal products, Oxazep should be withdrawn gradually to minimise the potential of increased seizure frequency.
Drug Classes
Adjunct anti-epileptic drugs
Mode Of Action
The pharmacological activity of Oxetol 300 mg is primarily exerted through the metabolite derivative (the monohydroxy derivative, MHD) of Oxetol 300 mg. The mechanism of action of Oxetol 300 mg and MHD is thought to be mainly based on blockade of voltage-sensitive sodium channels, thus resulting in stabilization of hyper excited neural membranes, inhibition of repetitive neuronal firing and diminishment of propagation of synaptic impulses.
Pregnancy
Pregnancy: Data on a limited number of pregnancies indicate that Oxetol 300 mg may cause serious birth defects (e.g. cleft palate) when administered during pregnancy. In the newborn child. Bleeding disorders in the newborn caused by antiepileptic agents have been reported. As a precaution, vitamin K1 should be administered as a preventive measure in the last few weeks of pregnancy and to the newborn. Oxetol 300 mg and its active metabolite (MHD) cross the placenta. Neonatal and maternal plasma MHD concentrations were similar in one case.Lactation: Oxetol 300 mg and its active metabolite (MHD) are excreted in human breast milk. Therefore, Oxazep should not be used during breast-feeding.
Frequently Asked Questions
What is Oxetol 300 mg used for?
Oxcarbazepine is indicated for:Adults: Monotherapy or adjunctive therapy in the treatment of partial seizuresPediatrics: Monotherapy in the treatment of partial seizures in children 4-16 years Adjunctive therapy in the treatment of partial seizures in children 2–16 years
What is the dosage of Oxetol 300 mg?
Adults: initiate with a dose of 600 mg/day, given twice-a-day Adjunctive Therapy: Maximum increment of 600 mg/day at approximately weekly intervals. The recommended daily dose is 1200 mg/day Conversion to Monotherapy: withdrawal concomitant over 3 to 6 weeks;reach maximum dose of Oxcarbazepine in 2 to 4 weeks with increments of 600 mg/day at weekly intervals to a recommended daily dose of 2400 mg/…
What are the side effects of Oxetol 300 mg?
The most commonly reported adverse reactions are somnolence, headache, dizziness, diplopia, nausea; vomiting and fatigue. Very rarely clinically significant hyponatraemia can develop during Oxazep use. Class I (immediate) hypersensitivity reactions including rash, pruritus, urticaria, angioedema and reports of anaphylaxis have been received.
Who should not take Oxetol 300 mg?
It is contraindicated to patients with hypersensitivity to the active substance or to any of the excipients.
What precautions should be taken with Oxetol 300 mg?
Alcohol: Caution should be exercised if alcohol is taken in combination with Oxazep therapy, due to a possible additive sedative effect.Withdrawal: As with all antiepileptic medicinal products, Oxazep should be withdrawn gradually to minimise the potential of increased seizure frequency.
Is Oxetol 300 mg safe during pregnancy and breastfeeding?
Pregnancy: Data on a limited number of pregnancies indicate that Oxcarbazepine may cause serious birth defects (e.g. cleft palate) when administered during pregnancy. In the newborn child. Bleeding disorders in the newborn caused by antiepileptic agents have been reported. As a precaution, vitamin K1 should be administered as a preventive measure in the last few weeks of pregnancy and to the newbo…
Disclaimer
The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.